Health Condition 1: K08- Other disorders of teeth and supporting structures
Conditions
Interventions
Intervention1: Pharmacotherapy group: All the patients in Control Group- A [Pharmacotherapy group] will be prescribed Flexon MR [Ibuprofen(400mg) +Paracetamol(325mg) +Chlorzoxazone(250mg)] twice a day
Sponsors
Dr Rupali Raj
Eligibility
Inclusion criteria
Inclusion criteria: 1.Patients between the age group 18-60 years diagnosed with myofascial pain syndrome (MPS) with at least 3 months history of MPS. 2.The diagnosis of MPS will be based on the criteria described by Travell and Simons (5 major and minimum 1 minor criteria are required for clinical diagnosis)
Exclusion criteria
Exclusion criteria: 1.Patients having orofacial pain due to odontogenic causes, neuralgia, migraine or due to cervical disc herniation 2.Patients with Neuromuscular disorders including orofacial dystonia, diseases causing muscle incoordination(ataxia) affecting mastication 3.Patients with general inflammatory connective tissue disease (e.g., rheumatoid arthritis) 4.Patients having osteoarthritis involving TMJ 5.Patients with previous surgery in the temporomandibular region. 6.Patients having other conditions that might affect the temporomandibular joint (TMJ). 7.Patients having Orofacial pain secondary to maxillo-facial trauma. 8.Patients having local skin infection over the masseter or temporalis muscle 9.Patients with ear infections 10.Patients with severe Parafunctional habits that require occlusal splints or night guard 11.Patients with severe malocclusion (Anterior open bite, any cross-bite, and overjet greater than 6mm, open bite in anterior region, decreased vertical dimension) requiring orthodontic treatment or patients with any dentofacial or skeletal deformities 12. Multiple posterior teeth missing or completely edentulous patients requiring prosthesis 13.Patients with photosensitivity disorder or those taking medication that increase light sensitivity. 14.Patients with a history of Epilepsy 15.Patients with Psychiatric disorder 16.Patients with 17. history of allergy to thiocolchicoside or chlorzoxazone, 18.renal or hepatic impairment 19.Patients with 20.history of allergy to thiocolchicoside or chlorzoxazone, 21renal or hepatic impairment 18.Patients with a history of renal or hepatic impairment 19.Patients with cancer and undergoing chemotherapy or Tumors treated with radiotherapy related to the TMJ region 20.Pregnancy and lactation 21. Patients with a history of allergy to Ibuprofen, diclofenac (or other NSAIDs), Paracetamol, Chlorzoxazone and Ethyl chloride
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Reduction in pain intensity measured using Visual Analog Scale VAS, stress scale, quality of life scale.Timepoint: recorded at the base line (First Visit), at the end of 1st, 2nd, 3rd and 4th week of commencement of treatment and then after one month of completion of the treatment. (Total-6 times) | — |
Secondary
| Measure | Time frame |
|---|---|
| Improvement in mouth opening & muscle tendernessTimepoint: Recorded at the base line (First Visit), at the end of 1st, 2nd, 3rd & 4th week of commencement of treatment & then after one month of completion of the treatment. (Total-6 times) | — |
Countries
India
Contacts
Public ContactDr Sangeeta Malik
subharti Dental college, swami vivekanand subharti university
Outcome results
None listed